The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
Junsheng FanTszhei FongZengfei XiaJian ZhangPeng LuoPublished in: Cancer medicine (2018)
ALK+ NSCLC patients treated with ALKi tend to have longer PFS than those treated with chemotherapy. ALKi-naïve patients tended to response better than their ALKi-pretreated counterparts. Alectinib appeared to be preferable for treating brain metastases due to its high intracranial efficacy. Patients treated with alectinib or ceritinib tended to have higher ORR and DCR than patients with similar baselines treated with crizotinib or chemotherapy. No significant differences in discontinuation rate were found for alectinib, ceritinib, crizotinib, and chemotherapy.
Keyphrases
- advanced non small cell lung cancer
- brain metastases
- small cell lung cancer
- locally advanced
- newly diagnosed
- epidermal growth factor receptor
- end stage renal disease
- chronic kidney disease
- ejection fraction
- squamous cell carcinoma
- peritoneal dialysis
- radiation therapy
- combination therapy
- patient reported outcomes
- smoking cessation
- replacement therapy